ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2020
Strong sales growth during January; Zinzino group revenue increased with a total of 43%, compared with the previous year.
The revenue in January for Zinzino's sales markets increased by 39% to MSEK 78.0 (56.1) due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 105% and amounted to MSEK 7.3 (3.6). Overall the Group increased revenues by 43% to MSEK 85.3 (59.7) compared with the previous year.
Revenues distributed as follows:
|Regions,MSEK||20-jan||19-jan||Change||YTD 2020||YTD 2019||Change|
|Europe Other Markets||35.7||14.6||145%||35.7||14.6||145%|
The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15:00 the 7th of February 2020.
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.